(Q40931968)

25 September 2017

title

Use of viral resistance patterns to antiretroviral drugs in optimising selection of drug combinations and sequences (English)

1 reference

25 September 2017

G J Moyle

1

1 reference

25 September 2017

publication date

1 August 1996

1 reference

25 September 2017

1 reference

25 September 2017

volume

52

1 reference

25 September 2017

issue

2

1 reference

25 September 2017

page(s)

168-185

1 reference

Limited sequence diversity of the HIV type 1 protease gene from clinical isolates and in vitro susceptibility to HIV protease inhibitors

25 September 2017

cites work

1 reference

12 December 2020

Novel mutation (V75T) in human immunodeficiency virus type 1 reverse transcriptase confers resistance to 2',3'-didehydro-2',3'-dideoxythymidine in cell culture

1 reference

12 December 2020

Combination therapy with zidovudine prevents selection of human immunodeficiency virus type 1 variants expressing high-level resistance to L-697,661, a nonnucleoside reverse transcriptase inhibitor

1 reference

12 December 2020

pol mutations conferring zidovudine and didanosine resistance with different effects in vitro yield multiply resistant human immunodeficiency virus type 1 isolates in vivo

1 reference

12 December 2020

Mutagenic study of codons 74 and 215 of the human immunodeficiency virus type 1 reverse transcriptase, which are significant in nucleoside analog resistance

1 reference

12 December 2020

Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase

1 reference

12 December 2020

Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine

1 reference

12 December 2020

Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides.

1 reference

12 December 2020

Didanosine resistance in HIV-infected patients switched from zidovudine to didanosine monotherapy.

1 reference

12 December 2020

Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides

1 reference

12 December 2020

HIV-1-specific reverse transcriptase inhibitors show differential activity against HIV-1 mutant strains containing different amino acid substitutions in the reverse transcriptase

1 reference

12 December 2020

Genotypic and phenotypic analysis of human immunodeficiency virus type 1 isolates from patients on prolonged stavudine therapy

1 reference

12 December 2020

Persistence of azidothymidine-resistant human immunodeficiency virus type 1 RNA genotypes in posttreatment sera

1 reference

12 December 2020

Human immunodeficiency virus type 1 (HIV-1) viremia changes and development of drug-related mutations in patients with symptomatic HIV-1 infection receiving alternating or simultaneous zidovudine and didanosine therapy

1 reference

12 December 2020

A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors

1 reference

12 December 2020

In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors

1 reference

12 December 2020

Nonhomogeneous distribution of human immunodeficiency virus type 1 proviruses in the spleen

1 reference

12 December 2020

Quantitation of zidovudine-resistant human immunodeficiency virus type 1 in the blood of treated and untreated patients

1 reference

12 December 2020

Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection. A phase I/II study

1 reference

12 December 2020

Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine

1 reference

12 December 2020

Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture

1 reference

12 December 2020

Current knowledge and future prospects for the use of HIV protease inhibitors

1 reference

12 December 2020

Human immunodeficiency virus type 1 variants with increased replicative capacity develop during the asymptomatic stage before disease progression

1 reference

12 December 2020

Clinical correlates of in vitro HIV-1 resistance ot zidovudine. Results of the Multicentre Canadian AZT Trial

1 reference

12 December 2020

Genomic variation of human immunodeficiency virus type 1 (HIV-1): molecular analyses of HIV-1 in sequential blood samples and various organs obtained at autopsy.

1 reference

12 December 2020

Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects

1 reference

12 December 2020

Alternating nevirapine and zidovudine treatment of human immunodeficiency virus type 1-infected persons does not prolong nevirapine activity.

1 reference

12 December 2020

Influence of Emergence of Viral Resistance on HIV Treatment Choice

1 reference

12 December 2020

Reduced sensitivity to saquinavir: an update on genotyping from phase I/II trials

1 reference

12 December 2020

HIV-1 Drug Resistance: Molecular Pathogenesis and Laboratory Monitoring

1 reference

12 December 2020

Characterization of genetic variation and 3'-azido-3'-deoxythymidine- resistance mutations of human immunodeficiency virus by the RNase A mismatch cleavage method

1 reference

12 December 2020

High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection

1 reference

12 December 2020

Human immunodeficiency virus type 1-specific [2',5'-bis-O-(tert- butyldimethylsilyl)-beta-D-ribofuranosyl]-3'-spiro-5"-(4"-amino-1",2"- oxathiole-2",2"-dioxide)-purine analogues show a resistance spectrum that is different from that of the human imm

1 reference

12 December 2020

Study of human immunodeficiency virus resistance to 2'-3'-dideoxyinosine and zidovudine in sequential isolates from pediatric patients on long-term therapy

1 reference

12 December 2020

Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor

1 reference

12 December 2020

Resistance to AZT and ddC during long-term combination therapy in patients with advanced infection with human immunodeficiency virus.

1 reference

12 December 2020

HIV treatment choice based on resistance patterns.

1 reference

12 December 2020

Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection

1 reference

12 December 2020

HIV-1, the brain, and combination therapy

1 reference

12 December 2020

Long-term persistence of zidovudine resistance mutations in plasma isolates of human immunodeficiency virus type 1 of dideoxyinosine-treated patients removed from zidovudine therapy

1 reference

12 December 2020

Changes in drug sensitivity of human immunodeficiency virus type 1 during therapy with azidothymidine, dideoxycytidine, and dideoxyinosine: an in vitro comparative study

1 reference

12 December 2020

HIV-1 RNA serum-load and resistant viral genotypes during early zidovudine therapy

1 reference

12 December 2020

Extensive variation of human immunodeficiency virus type-1 in vivo

1 reference

12 December 2020

Zidovudine resistance, syncytium-inducing phenotype, and HIV disease progression in a case-control study. The VA Cooperative Study Group

1 reference

12 December 2020

Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors

1 reference

12 December 2020

Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment. AIDS Clinical Trials Group 116B/117 Study Team and the Virology Committee Resistance

1 reference

12 December 2020

Natural occurrence of drug resistance mutations in the reverse transcriptase of human immunodeficiency virus type 1 isolates

1 reference

12 December 2020

Dideoxynucleoside resistance emerges with prolonged zidovudine monotherapy. The RV43 Study Group

1 reference

12 December 2020

Genetic diversity and evolution of retroviruses.

1 reference

12 December 2020

Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes

1 reference

12 December 2020

Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro

1 reference

12 December 2020

Antiviral and pharmacokinetic properties of C2 symmetric inhibitors of the human immunodeficiency virus type 1 protease

1 reference

12 December 2020

Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy

1 reference

12 December 2020

Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents

1 reference

12 December 2020

Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus.

1 reference

12 December 2020

A nonnucleoside reverse transcriptase inhibitor active on human immunodeficiency virus type 1 isolates resistant to related inhibitors

1 reference

12 December 2020

Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party

1 reference

12 December 2020

High-level resistance to (-) enantiomeric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase

1 reference

12 December 2020

Human immunodeficiency virus type 1 pol gene mutations in an AIDS patient treated with multiple antiretroviral drugs

1 reference

12 December 2020

In vivo comparison of zidovudine resistance mutations in blood and CSF of HIV-1-infected patients.

1 reference

12 December 2020

A mutation in human immunodeficiency virus reverse transcriptase and decline in CD4 lymphocyte numbers in long-term zidovudine recipients

1 reference

12 December 2020

3'-Azido-3'-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors

1 reference

12 December 2020

Zidovudine phosphorylation in HIV-infected patients and seronegative volunteers

1 reference

12 December 2020

HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy

1 reference

12 December 2020

Detection of human immunodeficiency virus type 1 clinical isolates with reduced sensitivity to zidovudine and dideoxyinosine by RNA.RNA hybridization

1 reference

12 December 2020

Protein binding of human immunodeficiency virus protease inhibitor KNI-272 and alteration of its in vitro antiretroviral activity in the presence of high concentrations of proteins

1 reference

12 December 2020

HIV-1 sensitivity to zidovudine and clinical outcome in children

1 reference

12 December 2020

Human immunodeficiency virus type 1 pol gene mutations which cause decreased susceptibility to 2',3'-dideoxycytidine

1 reference

12 December 2020

Virological and immunological analysis of a triple combination pilot study with loviride, lamivudine and zidovudine in HIV-1-infected patients.

1 reference

12 December 2020

Divergent anti-human immunodeficiency virus activity and anabolic phosphorylation of 2',3'-dideoxynucleoside analogs in resting and activated human cells.

1 reference

12 December 2020

Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase

1 reference

12 December 2020

Resistance to 2',3'-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase

1 reference

12 December 2020

Resistance of HIV Type 1 to Proteinase Inhibitor Ro 31-8959

1 reference

12 December 2020

HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy

1 reference

12 December 2020

Susceptibilities of zidovudine-susceptible and -resistant human immunodeficiency virus isolates to antiviral agents determined by using a quantitative plaque reduction assay

1 reference

12 December 2020

Individualisation of HIV therapy: the clinician's perspective

1 reference

12 December 2020

Genetic differences between blood- and brain-derived viral sequences from human immunodeficiency virus type 1-infected patients: evidence of conserved elements in the V3 region of the envelope protein of brain-derived sequences

1 reference

12 December 2020

Synergistic inhibition of replication of human immunodeficiency virus type 1, including that of a zidovudine-resistant isolate, by zidovudine and 2',3'-dideoxycytidine in vitro

1 reference

12 December 2020

Antiviral drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase occur in specific RNA structural regions

1 reference

12 December 2020

Zidovudine induces the expression of cellular resistance affecting its antiviral activity.

1 reference

12 December 2020

Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase

1 reference

12 December 2020

Failure of antiretroviral therapy: role of viral and cellular factors

1 reference

12 December 2020

Zidovudine-resistant variants of HIV-1 in brain.

1 reference

12 December 2020

A short-term clinical evaluation of L-697,661, a non-nucleoside inhibitor of HIV-1 reverse transcriptase. L-697,661 Working Group

1 reference

12 December 2020

Zidovudine-resistant and -sensitive HIV-1 isolates from patients on drug therapy: in vitro studies evaluating level of replication-competent viruses and cytopathogenicity

1 reference

12 December 2020

Zidovudine sensitivity of human immunodeficiency viruses from high-risk, symptom-free individuals during therapy

1 reference

12 December 2020

Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations.

1 reference

12 December 2020

Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease

1 reference

12 December 2020

Selection in vitro of an HIV-1 variant resistant to both lamivudine (3TC) and zidovudine

1 reference

12 December 2020

Reduction of the in vitro activity of A77003, an inhibitor of human immunodeficiency virus protease, by human serum alpha 1 acid glycoprotein.

1 reference

12 December 2020

Drug resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy. The AIDS Clinical Trials Group 143 Virology Team

1 reference

12 December 2020

Generation and characterization of a human immunodeficiency virus type 1 (HIV-1) mutant resistant to an HIV-1 protease inhibitor

1 reference

12 December 2020

Identification of a novel human immunodeficiency virus strain cytopathic to megakaryocytic cells.

1 reference

12 December 2020

Quasispecies dynamics and the emergence of drug resistance during zidovudine therapy of HIV infection.

1 reference

12 December 2020

The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidine

1 reference

12 December 2020

Characterization of HIV isolates arising after prolonged zidovudine therapy

1 reference

12 December 2020

Development of HIV-1 resistance to (-)2'-deoxy-3'-thiacytidine in patients with AIDS or advanced AIDS-related complex.

1 reference

12 December 2020

Two-Drug Combinations of Zidovudine, Didanosine, and Recombinant Interferon- A Inhibit Replication of Zidovudine-Resistant Human Immunodeficiency Virus Type 1 Synergistically In Vitro

1 reference

12 December 2020

Pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy

1 reference

12 December 2020

Combination therapy with zidovudine and didanosine compared with zidovudine alone in HIV-1 infection

1 reference

12 December 2020

Active human immunodeficiency virus protease is required for viral infectivity

1 reference

12 December 2020

Structures of DNA and RNA polymerases and their interactions with nucleic acid substrates

1 reference

12 December 2020

Sensitivity of wild-type human immunodeficiency virus type 1 reverse transcriptase to dideoxynucleotides depends on template length; the sensitivity of drug-resistant mutants does not.

1 reference

12 December 2020

Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology Committee Resistance Working Group

1 reference

12 December 2020

Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959.

1 reference

12 December 2020

Correlates of zidovudine phosphorylation with markers of HIV disease progression and drug toxicity

1 reference

12 December 2020

Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy

1 reference

12 December 2020

HIV-1 Reverse Transcriptase Codon 215 Mutation and Clinical Outcome in Children Treated with Zidovudine

1 reference

12 December 2020

Development and significance of zidovudine resistance in children infected with human immunodeficiency virus

1 reference

12 December 2020

Evaluation of the efficacy and tolerance of R 018893, R 089439 (loviride) and placebo in asymptomatic HIV-1-infected patients. Loviride Collaborative Study Group

1 reference

12 December 2020

Identification of novel mutations that confer drug resistance in the human immunodeficiency virus polymerase gene.

1 reference

12 December 2020

Effect of stage of disease and drug dose on zidovudine susceptibilities of isolates of human immunodeficiency virus

1 reference

12 December 2020

Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy.

1 reference

12 December 2020

Viral dynamics in human immunodeficiency virus type 1 infection

1 reference

12 December 2020

Biological comparison of wild-type and zidovudine-resistant isolates of human immunodeficiency virus type 1 from the same subjects: susceptibility and resistance to other drugs

1 reference

12 December 2020

Isolation of drug-resistant variants of HIV-1 from patients on long-term zidovudine therapy

1 reference

12 December 2020

Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor

1 reference

12 December 2020

Detection of Mutations Associated with Zidovudine Resistance in Human Immunodeficiency Virus by Use of the Polymerase Chain Reaction

1 reference

12 December 2020

Zidovudine treatment results in the selection of human immunodeficiency virus type 1 variants whose genotypes confer increasing levels of drug resistance.

1 reference

12 December 2020

10.2165/00003495-199652020-00002

Identifiers

DOI

1 reference

Dimensions Publication ID

25 September 2017

1027262842

0 references

1 reference